Information Provided By:
Fly News Breaks for August 13, 2019
NVS, AMGN
Aug 13, 2019 | 07:23 EDT
Oppenheimer analyst Jay Olson raised his price target for Amgen (AMGN) to $230 from $210 after the U.S. District Court determined that Sandoz has not met the burden to prove all seven asserted claims invalid and upheld several Enbrel patents. The analyst suspects Sandoz will appeal but views the outcome as highly favorable for Amgen and models flat Enbrel sales until 2021 before declining. Sandoz is a division of Novartis (NVS). Olson reiterates an Outperform rating on Amgen's shares.
News For AMGN;NVS From the Last 2 Days
NVS
NVS
Apr 24, 2024 | 07:26 EDT
TD Cowen analyst Yaron Werber raised the firm's price target on BeiGene (BGNE) to $236 from $235 and keeps a Buy rating on the shares. The firm updated its model to reflect lower collaborative revenue given termination of Novartis (NVS) agreement for tisle in Sep 2023.
NVS
NVS
NVS
NVS
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.